SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates TESS, STSA, CHRA

STSADelisted Stock  USD 1.10  0.01  0.90%   
About 62% of Satsuma Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Satsuma Pharmaceuticals suggests that many traders are alarmed regarding Satsuma Pharmaceuticals' prospects. The current market sentiment, together with Satsuma Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Satsuma Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
PRNewswire -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Read at prnewswire.com
prnewswire News
  

Satsuma Pharmaceuticals Fundamental Analysis

We analyze Satsuma Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satsuma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satsuma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Book

Price To Book Comparative Analysis

Satsuma Pharmaceuticals is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Satsuma Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Satsuma Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Satsuma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Satsuma Pharmaceuticals Related Equities

MNOVMediciNova   6.50   
0%
90.0%
PHVSPharvaris   5.94   
0%
83.0%
TILInstil Bio   5.61   
0%
78.0%
ERASErasca   3.85   
0%
53.0%
KRONKronos Bio   3.45   
0%
48.0%
PMVPPmv Pharmaceuticals   2.55   
0%
35.0%
SNTISenti Biosciences   2.36   
0%
33.0%
CTMXCytomX Therapeutics   2.30   
0%
32.0%
FBRXForte Biosciences   2.30   
0%
32.0%
ASMBAssembly Biosciences   2.17   
0%
30.0%
PEPGPepGen   2.08   
0%
29.0%
CINGCingulate   1.51   
0%
21.0%
CYCNCyclerion Therapeutics   0.70   
0%
9.0%
LRMRLarimar Therapeutics   0.49   
0%
6.0%
ACHLAchilles Therapeutics   0.93   
13.0%
0%
ELYMEliem Therapeutics   2.60   
36.0%
0%
ADXNAddex Therapeutics   7.15   
100.0%
0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Satsuma Stock

If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes